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Background: According to the GOLD international guidelines, the treatment of chronic obstruc-
tive pulmonary disease (COPD) should be proportional to the severity of airflow obstruction
graded according to FEV1% predicted. Regular treatment with long-acting bronchodilators
should be prescribed for symptomatic patients with FEV1 < 80%. Inhaled corticosteroids should
be added in patients with FEV1 < 50% predicted and frequent exacerbations.
Aim: To investigate whether pulmonologists follow the GOLD guidelines when prescribing
treatment for COPD.
Methods: A multicenter, cross-sectional, observational study was carried out in 49 Pulmonary
Units evenly distributed throughout the country. For each patient the demographic, clinical
data and the current therapies were registered in an electronic database.
Results: 4094 patients (mean age: 70.9  9.4; males 72.4%, female 27.6%) were enrolled.
Disease severity was classified as: mild (745), moderate (1722), severe (923), very severe
(704). Irrespective of disease severity, inhaled corticosteroids alone or in combination with
long-acting bronchodilators were used in 15.2% and 66.8% of patients, respectively. The appro-
priateness of the pharmacological treatment of the COPD patients was defined in accordance
with the GOLD recommendations. The treatment was appropriate in 37.9% of patients and
inappropriate in 62.1%, p < 0.0001. The inappropriateness was due to under-prescription in
7.2% and to over-prescription in 54.9% of patients. The presence and the number of exacerba-
tions represented an important trigger for over-prescription at stages I and II.
Conclusions: This study shows that there is a poor relationship between the recommendations
of the GOLD international guidelines and current clinical practice, and that exacerbations may
play a role in over-prescription.
ª 2012 Elsevier Ltd. All rights reserved.Intensive Care Unit, Thoracic Physiopathology Laboratory, AOU Careggi, 50134 Florence, Italy.
areggi.toscana.it, acorrado@qubisoft.it (A. Corrado).
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and depression) were recorded. All centres were asked toCurrent international guidelines for COPD1e4 recommend
long-acting inhaled bronchodilators, including b2-agonists
(LABA) and antimuscarinic agents (LAMA) on a regular basis
as monotherapy or in combination with inhaled corticoste-
roids (ICS) for the symptomaticmanagement of COPDand the
prevention of exacerbations.5e7 However, a significant
dissociation has been reported between guideline recom-
mendations and clinicians’ practices.8 Furthermore, despite
significant efforts to promote and disseminate the guide-
lines, they have not been commonly adopted or imple-
mented by primary care physicians or pulmunologists.9
In order to investigate whether Italian pulmonary
physicians follow international recommendations in regular
pharmacological treatment of stable COPD patients, the
Italian Association of Hospital Pneumologists (AIPO: Asso-
ciazione Italiana Pneumologi Ospedalieri) planned
a national survey involving 65 Pulmonary Units spread over
the national territory. In this study we compare the GOLD
recommendations with current clinical practice.
Methods
This observational, cross-sectional, non-interventional
multicentre study was carried out from 1st April 2009 to
30th November 2009 in outpatient clinics of Italian
Pulmonary Units spread over the National territory in
university, general and county hospitals. Sixty-five units
were selected by AIPO to take part in the survey. The
protocol was approved by the local ethics committees of all
the participating centres. All patients provided written
informed consent to participate in the study. All stable
COPD patients who were visited at the outpatients clinic of
the unit for the first time or for regular follow-ups were
considered eligible for the study and registered in the
electronic database developed by AIPO. In each unit, one
or more specialists filled out an electronic Case Report
Form (e-CRF) with clinical information on patients with
a confirmed diagnosis of COPD. The e-CRF required the
following basic information: demographic data, history of
smoking, spirometric evidence of the COPD diagnosis,
symptoms reported by the patient at the time of the visit,
the GOLD FEV1 staging, and current pharmacotherapy. All
the e-CRFs were sent on-line to the central database of the
AIPO Study Centre for data processing and analysis that was
blind with regard to the patient’s identity. The COPD
diagnosis was based on clinical history, physical examina-
tion and spirometric evaluation in a stable clinical condi-
tion, (FEV1/FVC lower than 70% after bronchodilators). The
degree of severity of COPD was established on the values of
the FEV1% predicted:
 Stage I e Mild COPD (FEV1  80% pred.);
 Stage II e Moderate COPD (50%  FEV1 < 80% pred.);
 Stage III e Severe COPD (30%  FEV1 < 50% pred.);
 Stage IV e Very severe COPD (FEV1 < 30% pred. or
FEV1 < 50% pred. with PaO2 < 60 mmHg).
The medical treatment of COPD and the following comor-
bidities (cardiovascular, diabetes, obesity, dyslipidemia,obstructive sleep apnoea, chronic renal failure, osteoporosis,
consecutively enroll within 9 months the patients who had
attended their units and complied with the following inclusion
criteria: aged over 40; smokers or ex-smokers; clinical diag-
nosis of COPD according to the GOLD guideline version existing
at the time of the study1; not fully reversible airflow obstruc-
tion (postbronchodilator FEV1/FVC ratio <0.7). For patients
who were visited for the first time, spirometry was performed
on enrolment, unless one was available from the previous
month.
All medical treatments were within normal clinical
practice, the decision to prescribe any treatment was
completely independent from the decision to include the
patient in the study.
The appropriateness of the pharmacological treatment
of COPD patients and the type of inappropriateness if
under- or over-prescribing, was established in accordance
with the GOLD guidelines.1
Under-prescription was defined as lack of:
I. regular treatment with LABA or LAMA in symptomatic
patients at stages II, III, IV.
II. prescription of ICS on top of long-acting bronchodila-
tors (LABA in general) in symptomatic patients with
frequent exacerbations (at least 1 per year in the last 3
years) in stages III and IV.
Over-prescription was defined as regular treatment with:
III. LABA or LAMA or ICS at stage I.
IV. ICS at stage II.
V. ICS on top of long-acting bronchodilators at stages I
and II.
VI. ICS on top of long-acting bronchodilators at stages III
and IV in patients without frequent exacerbations.
Correct prescription was defined as:VII. No regular treatment at stage I.
VIII. Regular treatment with LAMA or LABA (or both) in
symptomatic patients at stage II.
IX. Regular treatment with ICS on top of long-acting
bronchodilators, in general as fixed-dose combina-
tions (FDC) in patients with frequent exacerbations at
stages III and IV.
The Exclusion Criteria were as follows:
 clinical features suggesting bronchial asthma or
a previous physician’s diagnosis of asthma;
 refusal to participate;
 other de-compensated organ failures;
 known neoplastic diseases;
 severe psychiatric disorders.
Data analysis
The sample size of this study was established on the basis of
the expected national prevalence of COPD estimated at
How far is real life from COPD therapy guidelines? 9916%10 with a confidence interval of 1.53%, and assuming
a drop rate of 10%, therefore the theoretical number of
patients to be included was 3686. Results were given as
means (SD) for normally distributed data and as medians
with the Interquartile range (IQR), for non-normally
distributed variables. The analysis of variance for
repeated measurements was used to test the difference
between the means of several subgroups of a variable
(multiple testing). We defined the pharmacological treat-
ment as a binary variable (appropriate and inappropriate)
in accordance with the recommendation suggested by the
GOLD for the different stages of severity. Bivariate analyses
were conducted with the chi-square test (for categorical
variables) and two tailed t-tests. A p value of 0.05 was
considered statistically significant. Analyses were per-
formed by MedCalc (version 11.0.0.0).Results
Of the 65 Units involved in the study, 16 withdrew after
initial acceptance for technical reasons such as limited
internal organization or lack of time. The final data were
collected in 49 units. The geographical distribution of the
units was as follows: 19 (38.7%) in the north, 17 (34.7%) in
the centre, and 13 (26.5%) in the south of Italy. Six units
were in university hospitals and 43 in general and county
hospitals. On November 30th 2009, 4094 patients were
enrolled. The number of patients recruited by type of
hospital amounted to 3682 (88.5%) in general and county
hospitals, and 472 (11.5%) in university hospitals. By
geographical area, the enrolment was 1393 (34%) in the
north, 1784 (43.6%) in the centre, and 917 (22.4%) in the
south. The median number of cases contributed by units
was 76, and the interquartile range (IQR) was 47.5e106.5.
The diagnosis of COPD was established in 30% of the
patients before 2000, in 28% before 2005, and in 42%
between 2005 and 2009.
Characteristics of the patient population
Table 1 shows the characteristics of the patient population
as well as distribution among the GOLD stages. Interest-
ingly, almost 16% of COPD patients had never been smokers
and 8.5% of these were at the most severe stage, i.e. IV.
Comorbidities
As reported in Table 1, 74% of patients were suffering from
comorbidities. The comorbidity rate increased progres-
sively with the advancing disease severity from 64% to 74%
at the mild and moderate stages, to 77% and 81% at the
severe and very severe stages, respectively (Chi-square
trend 11,866, p Z 0.0006). Systemic hypertension alone
represented the most frequent comorbidity (52.4%).
Chronic heart failure, dilating cardiomyopathy and chronic
ischaemic cardiopathy together represented 26.5% of all
comorbidities. Obesity was present in 17.7% of patients,
diabetes in 12.1%, dyslipidemia in 10.2%, obstructive
sleep apnoea in 5.1%, and chronic renal failure, osteopo-
rosis, and depression in 1.8%, 3.1%, and 3.3%, respectively.Cardiovascular comorbidities including hypertension rep-
resented 78.8% of all comorbidities associated with COPD.
Exacerbation and hospitalization
Exacerbation was not reported in 110 patients. Out of
a total of 3984 patients, 62% reported at least one exac-
erbation during previous years. The number of exacerba-
tions ranged from 1 to 10, mean 2.17 (1.64); 95% IC
2.11e2.24. 1079 patients reported one exacerbation during
the previous year, whereas 1378 patients reported two or
more exacerbations. As the severity increased, the subset
of patients with two or more exacerbations showed
a steady and significant rise in the rate of exacerbations by
20.7 and 26.8% at stages I and II, and by 39.9 and 61.3% at
stages 3 and 4 p < 0.0001. (Table 1).
Nine-hundred and seventy-eight patients reported at
least one or more cases of hospitalization owing to respi-
ratory problems during the previous years. The number of
hospitalizations ranged from 1 to 10, mean 1.73 (1.28); 95%
IC 1.64e1.81. The severity of the disease seemed to affect
the hospitalization reported in the previous year, with the
proportion of patients who were hospitalized increasing
with the severity of disease. The subgroup of patients with
1 or more hospitalizations showed a statistically significant
increase in the percentage of hospitalizations from stage 1
(9.6%) to stage 4 (56.8%) p < 0.0001. Conversely, the
percentage of patients who were not hospitalized
decreased significantly from stage 1 (90.4%) to stage 4
(43.2%) p Z 0.0108, Table 1.
Pharmacological treatment
Out of the 4094 patients recruited, a total of 302 (7.4%), of
whom 263 at stages IeII and 39 at stages IIIeIV, did not
receive any regular pharmacological treatment for COPD;
the remaining 3792 (92.6%) received at least 1 drug on
a regular basis (pZ 0.0001). Of these patients 2786 (73.5%)
used bronchodilators, 578 (15.2%) ICS monotherapy, and
2534 (66.8%) ICS in combination with long-acting broncho-
dilators. One hundred and three patients (3.7%) took
systemic corticosteroids per os. on a regular basis. Table 2
illustrates the type of drugs used by the 3792 patients at
each stage of the disease. The long-acting antimuscarinic
agents were prescribed in all classes of disease severity,
ranging from 41 to 49.5% at stages I and II, and from 61 to
66.8% at stages III and IV, respectively. Out of the total
number of patients, LAMAs were prescribed in monotherapy
in 11% of cases, in 39% in combination with a FDC, and in 4%
with ICS. Inhaled corticosteroids in combination with Beta2
long-acting agonists like FDC were the most prescribed
drugs: 45.6 and 67.3% at stages I and II, 75.4 and 74.4% at
stages III and IV. FDC was employed alone in 24.8% of cases
and in 41.9% in combination with a long-acting bronchodi-
lator. ICS were used at all stages of the disease with the
highest percentage (19.6%) at stage IV and the lowest
(11.2%) at stage I, p Z 0.0192. ICS were employed in
monotherapy in 3.9% of cases, in 11.3% in association with
a long-acting bronchodilator. LABA were used in mono-
therapy in 4.1% of cases, in 3.7% in combination with ICS,
and in 2.7% associated with a long-acting bronchodilator.
Table 1 Characteristics of the patients according to the severity of COPD by GOLD stages.
Characteristics All patients
(N Z 4094)
Mild
(N Z 745)
18.2%
Moderate
(N Z 1722)
42.1%
Severe
(N Z 923)
22.5%
Very severe
(N Z 704)
17.2%
p value
Age, years, Mean (SD) 70.9 (9.4) 69.2 (10.0) 70.6 (9.6) 71.6 (8.9) 72.5 (8.5) <0.001a
Male sex, % 72.4 65.1 70.5 77.1 78.8 <0.0011b
Female sex, % 27.6 34.9 29.5 22.9 21.2
Current Smoker, % 24.8 27.2 28.0 22.2 17.9 <0.0001c
Ex Smoker, % 59.4 50.3 54.7 64.8 73.6
No Smoker, % 15.8 22.4 17.3 13.0 8.5
BMI (kg/m2), Mean (SD) 27.4 (5.3) 27.6 (4.8) 27.8 (5.3) 26.9 (5.1) 27.0 (5.8) <0.001d
Presence of at least 1 comorbidity, % 74 64 73.6 77 81.3 Z0.0006e
Characteristics All patients
(N Z 3984)
Mild
(N Z 726)
Moderate
(N Z 1677)
Severe
(N Z 893)
Very severe
(N Z 688)
p value
Exacerbations: 0, % (1527) 38.3 55.5 42.6 32.6 17.3 Z0.0001f
Z1, % (1079) 27.1 23.8 30.6 27.5 21.4 Z0.5702g
>2, % (1378) 34.6 20.7 26.8 39.9 61.3 <0.0001h
Hospitalization: 0, % (3006) 75.4 90.4 84.0 72.2 43.2 Z0.0108i
>1, % (978) 24.6 9.6 16.0 27.8 56.8 <0.0001j
In 110 patients data on the number of exacerbations and hospitalizations were not reported, so 3984 patients were included in the
analysis.
a ANOVA, One-way analysis of variance, F-ratio 17,526.
b Chi-square test for trend: Chi-square (trend) 10,701.
c Chi-square test: Chi-square 121,315; combining Ex Smoker and No Smoker Vs Smoker : Chi-square (trend) 26,990, p < 0.0001.
d ANOVA, One-way analysis of variance, F-ratio 6660.
e Chi-square (trend) 11.866.
f Chi-square (trend) 12.569.
g Chi-square (trend) 0.481.
h Chi-square (trend) 47.093.
i Chi-square (trend) 5.730.
j Chi-square (trend) 72.870.
992 A. Corrado, A. RossiThe percentage of patients treated with 1 or more drugs for
each stage of the disease is illustrated in Fig. 1.
Of the 3792 patients with at least one drug, 102 were
excluded from the subsequent analysis as the number of
exacerbations had not been recorded in the CRF. The
treatment in the remaining 3690 was classified on the basis
of the GOLD guidelines (see Methods) as appropriate in 1399
patients (37.9%) and inappropriate in 2291 (62.1%),
p < 0.0001. The inappropriateness was due to under-
prescription in 267 patients (7.2%) and to over-
prescription in 2024 (54.9%). Fig. 2 illustrates the patternsTable 2 Type of treatment by Disease’s severity in 3792 patien
Treatment All patients
(N Z 3792)
Mild
(N Z 642)
17%
Mode
(N Z
41%
LAMA, % 54 41 49.5
LABA, % 10.5 15 11
FDC, % 66.8 45.6 67.3
ICS, % 15.2 11.2 14.5
SABA, % 6.3 10.3 4.9
Xanthine, % 2.2 1.3 1.4
SABA/SAMA, % 1.6 0.3 1
Other, % 0.6 0.5 0.4of correct, under- and over-prescription according to
disease severity grouped in Stages IeII and IIIeIV. Table 3
illustrates the patterns of prescription in patients without
exacerbations versus those with 1 or 2 exacerbations. The
pharmacological treatment of patients without exacerba-
tion was over-prescribed in 80 and 74% of patients at stages
I and II, in 80 and 82% of patients at stages III and IV. The
treatment was under-prescribed in 5% of patients at stage
II, and in 9 and 12% of patients at stages III and IV,
respectively. Patients with 1 exacerbation presented a high
rate of over-prescription at stages I (85%) and II (79%) whichts who received at least one drug.
rate
1562)
Severe
(N Z 893)
24%
Very severe
(N Z 695)
18%
p value
61 66.8 Z0.0001
8.7 7.8 Z0.1815
75.4 74.4 Z0.0001
15.9 19.6 Z0.0192
5.5 6.6 Z0.6832
3.5 3 Z0.0814
2.5 3.2 Z0.5883
0.9 0.7 Z0.1424
Figure 1 Pharmacological treatment by disease severity.
How far is real life from COPD therapy guidelines? 993dropped to 0% at stages III and IV, while under-prescription
ranged from 0% to 5% at stages I and II, and 17% and 11% at
stages III and IV. Patients with 2 exacerbations presented
a further increase in over-prescription at stages I (88%) and
II (84%) compared to those without (80 and 74%) or with
only 1 (85 and 79%) exacerbation, p < 0.0001 and
p Z 0.0022, respectively. Patients with 1 hospitalization
showed a similar pattern of inappropriateness to those with
2 exacerbations. There was no difference in the rate of
over-prescription at stages I (84% vs. 88%, p Z 0.5954), II
(80% vs. 84% p Z 0.2321), III and IV (0% for both), respec-
tively; under-prescription was 0% for both groups at stage I,
5% vs. 4% (pZ 0.6852) at stage II, 15% vs. 12% (pZ 0.3584)
at stage III and 15% vs. 13% (p Z 0.4764) at stage IV,
respectively. Fig. 3 shows the type of drugs used in patients
with or without exacerbations. FDC alone or in combination
with LAMA were the most frequently prescribed drugs at all
stages of severity in both groups of patients. When
considering both FDC alone and FDC with LAMA, the rate of
over-prescription at stages I and II in patients without
exacerbations was 40 and 64%, respectively, whichFigure 2 Patterns of correct, under and over-prescription by
disease severity in 3792 patients treated regularly with at least
one drug.increased to 58 and 72% in the presence of 1 exacerba-
tion. At stages III and IV the rate of over-prescription was 64
and 78% in patients without exacerbations, which dropped
to 0% in the presence of 1 exacerbation. The prescription
rate was not influenced by geographical distribution, as
reported in Table 4. No difference in the rate of under- or
over-prescribing was ascertained between university
hospitals (4.2% and 51%) and the district units (7.6% and
55%) p Z 0.8543 and 0.2819, respectively.Discussion
The data of our study show a dissociation between the
guidelines recommendations1 and therapies that Italian
clinicians prescribe for patients with stable COPD in their
clinical practice. A low rate of adherence to guideline
recommendations for COPD patients has also been reported
in other countries.8,11 A recent Italian study by Cazzola et
al.12 reported that General Practitioners prescribe treat-
ment without taking into account the severity of airway
obstruction, and COPD patients are generally under-
treated. More recently, the same Author,13 using the
same database, reported a reduction in the prescription of
FDC from 55.9% of patients with COPD in 2006 to 47.8% in
2008.13 Our data pertaining to a large number of patients
confirm an inappropriate use of ICS, though the patients of
our study referred to specialist centres. We consider our
data reliable since collected by Pulmonary Units in all
regions of Italy by Pneumonologists who volunteered for the
study purely for scientific interest.
There are several reasons for the discrepancy between
guidelines and clinical practice. (1) Institutions do not nor-
mally encourage the implementation of the Guidelines in
clinical practice. (2) The individual clinician sees the
Guidelines as an interference in her/his freedom of clinical
judgement. (3) In the case of COPD, the over-prescription of
ICS suggests that the differential diagnosis between asthma
and COPD is not sufficiently stressed and that FDC enjoy
a reputation of being an effective and safe drug in both
diseases, essentially deriving from its effectiveness in the
treatment of asthma.14 A recent NewZealand study reported
that asthma was the predominant COPD phenotype of the
patients studied.15 The distinction between chronic asthma
and COPD might not always be clear. However, patients with
asthma and a fixed airway obstruction have a pulmonary
function pattern that differs from that of classic COPD
patients.16 Recognizing and understanding the differences
between asthma and COPD may offer new insight into the
mechanisms and treatment of chronic pulmonary diseases.17
(4) Finally, it might well be that the available Guidelines are
to some extent insufficient for real life. For example, the
staging of COPD based on FEV1% predicted does not take into
account other fundamental issues in the pathophysiology of
COPD, such as pulmonary hyperinflation, expiratory flow
limitation, exercise capacity and tolerance. All these are
independent, poorly correlated variables.
Furthermore, the rate and severity of exacerbations are
only mentioned in the Guidelines with regard to severe and
very severe stages. It has recently been reported that
a history of previous exacerbations represents the major
determinant of frequent exacerbations at all GOLD
Table 3 Patterns of correct, under, over-prescription by disease severity in 3690 patients with no exacerbation vs 1and 2
exacerbations.
No Exacerbation
(1360)
1 Exacerbation
(990)
2 Exacerbations
(1340)
p value
Stage I, No of pats 335 146 144
Correct 67/335 (20%) 22/146 (15%) 18/144 (12%) Z 0.2751
Under 0 0 0
Over 268/335 (80%) 124/146 (85%) 126/144 (88%) < 0.0001
Stage II, No of pats 631 463 427
Correct 133/631 (21%) 76/463 (16%) 52/427 (12%) Z0.6781
Under 34/631 (5%) 24/463 (5%) 15/427 (4%) Z0.7766
Over 464/631 (74%) 363/463 (79%) 360/427 (84%) Z0.0022
Stage III, No of pats. 278 236 351
Correct 30/278 (11%) 196/236 (83%) 307/351 (88%) <0.0001
Under 24/278 (9%) 40/236 (17%) 44/351 (12%) Z0.8966
Over 224/278 (80%) 0/236 (0%) 0/351 (0%) <0.0001
Stage IV, No of pats 116 145 418
Correct 7/116 (6%) 129/145 (89%) 362/418 (87%) <0.0001
Under 14/116 (12%) 16/145 (11%) 56/418 (13%) Z0.0066
Over 95/116 (82%) 0/145 (0%) 0/418 (0%) <0.0001
994 A. Corrado, A. Rossistages.18 This study reported that 22% of COPD patients had
frequent exacerbations at a moderate stage. Jenkins
et al.19 in a post-hoc analysis of the TORCH dataset,
reported that in moderate COPD patients (Stage II), the
treatment with a FDC was effective in reducing the rate of
exacerbation by 31% and the risk of death by 33%. These
figures were higher than those pertaining to the others
stages of the disease. In our population, the prevalence of
patients with 1 or 2 exacerbations during the previous
year was 63%, of which 12.4% and 38.2% at mild andFigure 3 Type of treatment by disease severity and patterns o
patients without or with 1 exacerbations.moderate stages, respectively. This may only in part
explain the over-use of some drugs, especially in patients at
stage II where the percentage of over-prescribing increased
in a statistically significant way in those with 1 (79%) or 2
exacerbations (84%) compared to those without exacerba-
tions (74%), p Z 0.0022. However, in 37% of patients
without exacerbations, the inappropriateness of treatment
was particularly high with over-prescribing ranging from 74
to 82% at all stages of severity. There is no logical expla-
nation for this point which needs to be further investigated.f correct, under and over-prescription by disease severity in
Table 4 Patterns of correct, under, over-prescription by disease severity in 3690 patients with 1 or more or without exa erbations in different geographical area.
North Centre South p value North C ntre South p value
No exacerbation
(470/1360)
No exacerbation
(611/1360)
No exacerbation
(279/1360)
1 Exacerbations
(826/2330)
 Exacerbations
(9 2/2330)
1 Exacerbations
(522/2330)
Stage I, No of pats 137 138 60 132 10 55
Correct 21/137 (15%) 40/138 (29%) 6/60 (10%) Z 0.9499 13/132 (10%) 12 103 (12%) 15/55 (27%) Z0.0046
Under 0 0 0 0 0 0
Over 116/137 (85%) 98/138 (71%) 54/60 (90%) Z0.9805 119/132 (90%) 91 103 (88%) 40/55 (73%) Z0.4333
Stage II, No of pats 224 269 138 290 42 178
Correct 49/224 (22%) 44/269 (16%) 40/138 (29%) Z0.3428 36/290 (13%) 57 422 (14%) 35/178 (20%) 0.0825
Under 8/224 (4%) 21/269 (8%) 5/138(4%) Z0.7118 15/290 (5%) 14 422 (3%) 10/178 (6%) 0.9839
Over 167/224 (74%) 204/269 (76%) 93/138 (67%) Z0.6080 239/290 (82%) 35 /422 (83%) 133/178 (75%) 0.5584
Stage III, No of pats. 71 152 55 207 25 129
Correct 12/71 (17%) 10/152 (6%) 8/55 (15%) Z0.5651 176/207 (85%) 21 /251 (87%) 109/129 (85%) Z0.9943
Under 1/71 (1%) 18/152 (12%) 5/55 (9%) Z0.1103 31/207 (15%) 33 251 (13%) 20/129 (15%) Z0.9824
Over 58/71 (82%) 124/152 (82%) 42/55 (76%) Z0.8170 0/207 (0%) 0/ 51 (0%) 0/129 (0%) Z0.7581
Stage IV, No of pats 38 52 26 197 20 160
Correct 1/38 (3%) 4/52 (8%) 2/26 (8%) Z0.3877 178/197 (90%) 18 /206 (88%) 132/160 (83%) Z0.5672
Under 3/38 (8%) 10/52 (19%) 1/26 (4%) Z0.8456 19/197 (10%) 25 206 (12%) 28/160 (17%) 0.0557
Over 34/38 (89%) 38/52 (73%) 23/26 (88%) Z0.9053 0/197 (0%) 0/ 06 (0%) 0/160 (0%) Z0.8863
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996 A. Corrado, A. RossiWhen we examined the prescription patterns no differ-
ences were found among the various geographical areas or
between the university and hospital units. It should be
stressed that at the present time none of the guidelines
incorporate patient priorities or values, both of which are
important elements in guideline development.20
A recent study9 reported that respiratory medications
prescribed for an unselected population with a wide range
of COPD severity complied poorly with the GOLD pharma-
cologic treatment guidelines but were correlated with the
number of prior respiratory healthcare visits.
We acknowledge that our study has several limitations.
The first is that in filling out the CRF, the pulmonary
specialist might have been a different doctor from the
caring physician. Furthermore, we did not record whether
the pharmacological prescription originated from a pulmo-
nologist, another specialist (geriatrist, internist, etc.) or
a general practitioner. The second, as previously
mentioned, was the fact that we did not ascertain whether
the patients were actually taking the prescribed medica-
tions. Finally, the population of this study was not the
result of an epidemiological design, but only represented
patients who referred to the clinic of the units participating
in the study. Nevertheless, the population is quite large,
i.e. 4000 COPD patients, evenly distributed over the
national territory, and very similar to the kind of COPD
patients reported in most clinical studies.
In conclusion, despite several limitations, our observa-
tional study provides two important messages:
1) The guidelines are not strictly followed by Pulmonary
specialists in their clinical practice. Communication
between Guideline Committees and Clinicians should
be improved.
2) The Guideline Committees should take this discrepancy
into account and try to understand whether the
guidelines might in fact fail to reflect real life and
therefore also need to be improved.COPD3-AIPO study group
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